Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
Earnings Recap For February 1
Aetna Finds Resistance After Q4 Report
Novartis agrees to performance-based pricing with key insurers for heart failure drug (Seeking Alpha)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Feb 2016BMO CapitalMaintainsOutperform
Feb 2016JefferiesMaintainsHold
Jan 2016JefferiesDowngradesBuyHold

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

View Comments and Join the Discussion!

Get Benzinga's Newsletters